CorMedix (CRMD) Net Cash Flow (2010 - 2025)
CorMedix (CRMD) posted Net Cash Flow of $96.3 million for Q4 2025, up 187.64% sequentially from -$109.9 million in Q3 2025, and up 1695.31% YoY from $5.4 million in Q4 2024.
CorMedix (CRMD) Net Cash Flow (2010 - 2025) Analysis & Trends
CorMedix has reported Net Cash Flow for 15 years, with the latest figure at $96.3 million in Q4 2025.
- Quarterly Net Cash Flow rose 1695.31% year-over-year to $96.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $105.1 million (up 3528.03% YoY) and the FY2025 annual result came in at $105.1 million, up 3528.03% from the prior year.
- Net Cash Flow climbed to $96.3 million in Q4 2025 per CRMD's latest filing, from -$109.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $96.3 million in Q4 2025 and troughed at -$109.9 million in Q3 2025.
- A 5-year average of $5.2 million and a median of -$4.4 million in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow tumbled 8611.45% in 2023, then jumped 1695.31% in 2025.
- Over 5 years, Net Cash Flow stood at -$13.0 million in 2021, then surged by 99.15% to -$111121.0 in 2022, then sank by 8611.45% to -$9.7 million in 2023, then jumped by 155.44% to $5.4 million in 2024, then surged by 1695.31% to $96.3 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $96.3 million, -$109.9 million, and $93.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 96.35 Mn |
| Dec 31, 2025 | 96.35 Mn |
| Sep 30, 2025 | -109.93 Mn |
| Sep 30, 2025 | -109.93 Mn |
| Jun 30, 2025 | 93.02 Mn |
| Jun 30, 2025 | 93.02 Mn |
| Mar 31, 2025 | 25.63 Mn |
| Mar 31, 2025 | 25.63 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Dec 31, 2024 | 5.37 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Sep 30, 2024 | 6.75 Mn |
| Jun 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -6.71 Mn |
| Mar 31, 2024 | -8.46 Mn |
| Mar 31, 2024 | -8.46 Mn |
| Dec 31, 2023 | -9.68 Mn |
| Dec 31, 2023 | -9.68 Mn |
| Sep 30, 2023 | 33.61 Mn |
| Sep 30, 2023 | 33.61 Mn |